A significant breakthrough for UK patients with a rare and debilitating liver condition, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.
This approval marks a new era in managing this chronic and autoimmune liver disease.
What is Primary Biliary Cholangitis?
Primary biliary cholangitis is a rare, chronic liver disease characterized by the destruction of the bile ducts within the liver, leading to cholestasis and liver fibrosis.
This condition predominantly affects women and can lead to severe symptoms such as itching, fatigue, and ultimately, liver failure if left untreated or inadequately managed.
The Approval of Elafibranor
Elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, has been approved based on the results of the pivotal Phase III ELATIVE trial. This trial demonstrated that elafibranor significantly improves biomarkers of disease progression compared to placebo.
The drug showed a biochemical response in 51% of patients treated, versus only 4% in the placebo group, highlighting its efficacy in managing PBC.
Findings from the ELATIVE Trial
Endpoint |
Elafibranor Group |
Placebo Group |
|---|---|---|
| Biochemical Response | 51% | 4% |
| Normalization of ALP | 15% | 0% |
| Reduction in Pruritus | ↑ (Significant) | → (No change) |
The trial also indicated that elafibranor was well-tolerated, with common adverse events including abdominal pain, diarrhea, nausea, and vomiting, similar to those experienced by the placebo group.
Impact on Patients
“Data from the pivotal phase 3 ELATIVE clinical trial demonstrated that Iqirvo is an effective second-line treatment for patients with PBC with favorable benefit and risk data,”
said Dr. Kris Kowdley, Director at Liver Institute Northwest, Washington, and a primary investigator on the ELATIVE study.
This approval offers new hope for patients who have had inadequate responses to or unacceptable side effects from ursodeoxycholic acid (UDCA), the current standard treatment.
How Elafibranor Works
Elafibranor works by activating PPAR-alpha and PPAR-delta, which helps in reducing bile acid synthesis and targeting inflammation, cholestasis, and fibrosis associated with PBC. This dual action makes it a promising treatment for managing the disease progression and alleviating symptoms such as itching.
Safety and Tolerability
The safety profile of elafibranor has been consistent across various trials. While it is generally well-tolerated, patients should be aware of potential side effects such as weight gain, diarrhea, abdominal pain, and nausea.
The prescribing information includes warnings for risks such as myalgia, myopathy, and rhabdomyolysis, as well as adverse effects on fetal and newborn development.
In a Nutshell
The approval of elafibranor marks a significant milestone in the treatment of primary biliary cholangitis, offering a new and effective option for patients who have limited treatment choices.
As this medication becomes available, healthcare providers expect it to significantly enhance the quality of life for numerous individuals living with this rare and challenging condition.
For those affected by PBC, this breakthrough brings renewed hope and a better future in managing their disease.
Sources: THX News & Medicines and Healthcare products Regulatory Agency.
